Suchergebnisse - "Curigliano, G"

PubPharm (12)

1

Prognostic value of HER2DX in early-stage HER2-positive breast cancer : a comprehensive analysis of 757 patients in the Sweden Cancerome Analysis Network-Breast dataset (SCAN-B)

enthalten in: ESMO open | 2024

von Villacampa, G. | Pascual, T. | Brasó-Maristany, F. | +17

2

Trastuzumab deruxtecan (T-DXd) in HER2-low metastatic breast cancer treatment

enthalten in: Annals of oncology : official journal of the European Society for Medical Oncology | 2023

von Tarantino, P. | Tolaney, S. | Curigliano, G.

CommentOn: Ann Oncol. 2023 Oct;34(10):948-949. - PMID 37499869

3

Management of patients with HER2-positive metastatic breast cancer after trastuzumab deruxtecan failure

enthalten in: ESMO open | 2023

von Antonarelli, G. | Corti, C. | Tarantino, P. | +7

4

Patient-reported outcomes and hospitalization data in patients with HER2-positive metastatic breast cancer receiving trastuzumab deruxtecan or trastuzumab emtansine in the phase III DESTINY-Breast03 study

enthalten in: Annals of oncology : official journal of the European Society for Medical Oncology | 2023

von Curigliano, G. | Dunton, K. | Rosenlund, M. | +5

5

How I treat HER2-positive early breast cancer : how long adjuvant trastuzumab is needed?

enthalten in: ESMO open | 2022

von Morganti, S. | Bianchini, G. | Giordano, A. | +3

6

Tucatinib versus placebo added to trastuzumab and capecitabine for patients with pretreated HER2+ metastatic breast cancer with and without brain metastases (HER2CLIMB) : final overall survival analysis

enthalten in: Annals of oncology : official journal of the European Society for Medical Oncology | 2022

von Curigliano, G. | Mueller, V. | Borges, V. | +17

ErratumIn: Ann Oncol. 2023 Jul;34(7):630. - PMID 36564285

7

Final results from the PERUSE study of first-line pertuzumab plus trastuzumab plus a taxane for HER2-positive locally recurrent or metastatic breast cancer, with a multivariable approach to guide prognostication

enthalten in: Annals of oncology : official journal of the European Society for Medical Oncology | 2021

von Miles, D. | Ciruelos, E. | Schneeweiss, A. | +116

CommentIn: Ann Oncol. 2021 Oct;32(10):1206-1208. - PMID 34403778

8

Clinical development and current role of margetuximab for the treatment of breast cancer

enthalten in: Drugs of today (Barcelona, Spain : 1998) | 2021

von Tarantino, P. | Uliano, J. | Morganti, S. | +3

9

The global landscape of availability, accessibility and affordability of essential diagnostics and therapeutics for the management of HER2-positive breast cancer : The ONCOLLEGE-001 survey

enthalten in: Journal of cancer policy | 2021

von Trapani, D. | Lengyel, C. | Habeeb, B. | +8

10

The use of breast imaging for predicting response to neoadjuvant lapatinib, trastuzumab and their combination in HER2-positive breast cancer : Results from Neo-ALTTO

enthalten in: European journal of cancer (Oxford, England : 1990) | 2018

von Di Cosimo, S. | Campbell, C. | Azim, H. | +18